EMEA-002152-PIP03-19
Key facts
Invented name |
Darzalex
|
Active substance |
Daratumumab
|
Therapeutic area |
Oncology
|
Decision number |
P/0116/2020
|
PIP number |
EMEA-002152-PIP03-19
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of systemic light chain amyloidosis
|
Route(s) of administration |
|
Contact for public enquiries |
Janssen-Cilag International N.V.
E-mail: nreymond@its.jnj.com |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|